GlaxoSmithKline will acquire a stake in the Japanese subsidiary of Aspen Pharmacare Holdings as part of an alliance to boost commercial operations in the Asian country.

Glaxo will transfer distribution rights to some products in Japan to the unit, in which it will own a 25 percent stake.

The balance will be held by the South African company, also Africa’s biggest generic drugmaker.

Aspen has been seeking a partner in Japan to get better access to the fast-growing market, Chief Executive Officer Stephen Saad said in an interview with Bloomberg TV Africa last month.

Aspen is expanding in Asia, Latin America and sub-Saharan Africa to exploit growing demand for medicines in those regions and offset slower growth in its home market.

For further deal information visit Current Agreements (subscription required)

Related

Report: Partnering Deals and Alliances with GlaxoSmithKline

Report: Partnering Deals and Alliances with Aspen Pharmacare

Report: Top 50 Big Pharma Partnering and M&A Deal Trends

Browse: Complete Current Partnering report catalog

View: Partnering Scorecard in CP Insight– view top life science partnering deals by value

View: DealMetrics in CP Insight – the latest deal trend infographics for life science deal making

View: CP Insight’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: CP Insight’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter